Real-World Treatment Patterns After CD19-Directed CAR T Cell Therapy Among Patients with Diffuse Large B Cell Lymphoma

INTRODUCTION: CD19-directed chimeric antigen receptor T cells (CAR T) are approved for treatment of adults with relapsed/refractory diffuse large B cell lymphoma (DLBCL) following at least two lines of therapy. METHODS: This study describes real-world treatment patterns after CAR T in adults with DL...

Descripción completa

Detalles Bibliográficos
Autores principales: Jalbert, Jessica J., Wu, Ning, Chen, Chieh-I, Ambati, Srikanth, Ge, Wenzhen, Arnason, Jon E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9123047/
https://www.ncbi.nlm.nih.gov/pubmed/35397110
http://dx.doi.org/10.1007/s12325-022-02087-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9123047/
https://www.ncbi.nlm.nih.gov/pubmed/35397110
http://dx.doi.org/10.1007/s12325-022-02087-4

Ejemplares similares